edotreotide has been researched along with Abdominal Neoplasms in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Behe, M; Bucher, HC; Goetze, M; Heppeler, A; Jermann, E; Maecke, HR; Mueller-Brand, J; Otte, A; Roser, HW | 1 |
1 other study(ies) available for edotreotide and Abdominal Neoplasms
| Article | Year |
|---|---|
DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy.
Topics: Abdominal Neoplasms; Adult; Humans; Indium Radioisotopes; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Pentetic Acid; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Somatostatin; Sensitivity and Specificity; Yttrium Radioisotopes | 1997 |